Larimar Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Larimar Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-41.0%
Buyback Yield
| Total Shareholder Yield | -41.0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Oct 07Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans
Aug 09
Larimar Therapeutics: More Data Still Needed
Jul 15Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
May 31We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Larimar under pressure as FDA puts clinical hold on CTI-1601 program
May 26Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08
Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Dec 15Larimar completes dosing in Friedreich’s Ataxia, provides program update
Dec 08Larimar Therapeutics (LRMR) Investor Presentation - Slideshow
Nov 16Larimar Therapeutics reports Q3 results
Nov 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if LRMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LRMR's dividend payments have been increasing.
Dividend Yield vs Market
| Larimar Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (LRMR) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (LRMR) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate LRMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LRMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate LRMR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LRMR has not reported any payouts.